Physician profile
Jonathan Lebowitz
NPI 1801860812
$862.53
in general payments reported to CMS, 2019-2025
17 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $72.04 · 2023: $239 · 2024: $232 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.60 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $99.84 | 2023 | Livmarli |
| Otsuka America Pharmaceutical, INC. | $91.37 | 2023-2025 | Jynarque |
| Amgen INC. | $88.75 | 2024-2025 | Tavneos, Repatha, Krystexxa |
| Calliditas Therapeutics US INC. | $88.17 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals Lp | $81.80 | 2023-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $78.54 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.77 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $47.20 | 2023-2024 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.16 | 2024-2025 | |
| Travere Therapeutics, INC. | $35.42 | 2024-2025 | |
| Akebia Therapeutics INC | $34.44 | 2022-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $30.47 | 2025 | Terlivaz |
| Baxter Healthcare | $18.72 | 2022 | |
| Lilly USA, LLC | $16.66 | 2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $13.49 | 2023 | Crysvita |
| Vifor Pharma, INC. | $13.39 | 2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.